Results 231 to 240 of about 421,641 (311)

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. [PDF]

BMJ Open
Blackstone J, Williams T, Nicholas JM, Bordea E, De Angelis F, Bianchi A, Calvi A, Doshi A, John N, Apap Mangion S, Wade C, Merry R, Barton G, Lyle D, Jarman E, Mahad D, Shehu A, Arun T, McDonnell G, Geraldes R, Craner M, Hillier C, Ganesalingam J, Fisniku L, Hobart J, Spilker C, Robertson N, Kalra S, Pluchino S, Harikrishnan S, Mattoscio M, Harrower T, Young C, Lee M, Chhetri S, Ahmed F, Rog D, Silber E, Gallagher P, Duddy M, Straukiene A, Nicholas R, Rice C, Nixon SJ, Beveridge J, Hawton A, Tebbs S, Braisher M, Giovannoni G, Ciccarelli O, Greenwood J, Thompson AJ, Hunter R, Pavitt S, Pearson O, Evangelou N, Sharrack B, Galea I, Chandran S, Ford HL, Frost C, Chataway J.   +61 more
europepmc   +1 more source

<p>Comorbidities in multiple sclerosis—a plea for interdisciplinary collaboration to improve the quality of life of MS patients</p>

, 2019
Hans-Klaus Goischke
openalex   +2 more sources

Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials. [PDF]

Neurol Sci
Schilke ED, Remoli G, Funelli E, Galimberti M, Fusco ML, Cereda D, Balducci C, Frigo M, Cavaletti G.   +8 more
europepmc   +1 more source

Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS) [PDF]

Gabriel Bsteh, L. Escola, Harald Hegen, Ewald Lindner, Michael Khalil, S. Schneider, Gerhard Traxler, Erich Raithel, Christian Bsteh, Christoph Mitsch, Thomas Berger, Berthold Pemp, the Austrian Network for Optical Coherence in Multiple Sclerosis (AN-OCT-MS)   +12 more
openalex   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

The quality of life impact of the COVID-19 pandemic and lockdowns for people living with multiple sclerosis (MS): evidence from the Australian MS Longitudinal Study. [PDF]

Qual Life Res
Henson GJ, van der Mei I, Taylor BV, Blacklow P, Claflin SB, Palmer AJ, Hurst C, Campbell JA.   +7 more
europepmc   +1 more source

MS COSTAR: A PC Based Medical Information System to Support and Pool Data among Multiple Sclerosis Clinics.

, 1989
Donald R. Studney, Fred D. Lubin, Lisa Marcucci   +2 more
openalex   +1 more source

Plasma Proteomics Identifies TAOK3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target

Arthritis &Rheumatology, Accepted Article.
Objective Bone destruction associated with active rheumatoid arthritis (RA) remains a major therapeutic challenge, with a lack of reliable molecular markers reflecting bone injury. This study aims to identify novel biomarkers linked to bone destruction in active RA through proteomic analysis, providing new strategies for precise monitoring and targeted
Pengfei Xin, Wenzhen Li, Xinyu A, Jun Shen, Xiaohui Meng, Yanqin Bian, Haihui Han, Zheng Xiang, Lei Ran, Songtao Sun, Jun Xie, Tao Yue, Qi Zhu, Xiaoming Zhang, Lu Xie, Lianbo Xiao   +15 more
wiley   +1 more source

Molecular stratification of antiphospholipid syndrome through integrative analysis of the whole‐blood RNA transcriptome

Arthritis &Rheumatology, Accepted Article.
Objective Antiphospholipid syndrome (APS) is a thrombo‐inflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)‐positive patients using whole‐blood transcriptomics.
Amala Ambati, Feiyang Ma, Katarina Kmetova, Sherwin Navaz, Claire K. Hoy, Cyrus Sarosh, Ajay Tambralli, Erika Navarro‐Mendoza, Johann E. Gudjonsson, J. Michelle Kahlenberg, Jacqueline A. Madison, Alí Duarte‐García, Jason S. Knight, Yu Zuo   +13 more
wiley   +1 more source

Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

Frontiers in Immunology
Regina Berkovich, Jonathan Calkwood, Heidi Crayton, April Erwin, Simon Faissner, Ralf Gold, Joshua Katz, Mark Leekoff   +7 more
doaj   +1 more source